Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bunce

Showing results (181-190 of 186) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 186 results.
Research Square|June 12, 2025
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocolChristopher S Freet, Kirsten Shuler, Sarah Kawasaki, et al.
Addiction Science & Clinical Practice|October 31, 2025
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocolChristopher S Freet, Kirsten Shuler, Sarah Kawasaki, et al.
ESMO Open|August 31, 2024
Association of post-operative ctDNA detection with outcomes of patients with early breast cancersR Cutts, L Ulrich, M Beaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2025
Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionI Garcia-Murillas, C W Abbott, R J Cutts, et al.
Eye (London, England)|July 16, 2016
The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of careG Liew, A Y Lee, J Zarranz-Ventura, et al.
Addiction Science & Clinical Practice|July 26, 2024
Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorderChristopher S Freet, Brianna Evans, Timothy R Brick, et al.
Pageof 19

Showing results (181-190 of 186) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 186 results.
Research Square|June 12, 2025
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocolChristopher S Freet, Kirsten Shuler, Sarah Kawasaki, et al.
Addiction Science & Clinical Practice|October 31, 2025
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocolChristopher S Freet, Kirsten Shuler, Sarah Kawasaki, et al.
ESMO Open|August 31, 2024
Association of post-operative ctDNA detection with outcomes of patients with early breast cancersR Cutts, L Ulrich, M Beaney, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2025
Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionI Garcia-Murillas, C W Abbott, R J Cutts, et al.
Eye (London, England)|July 16, 2016
The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of careG Liew, A Y Lee, J Zarranz-Ventura, et al.
Addiction Science & Clinical Practice|July 26, 2024
Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorderChristopher S Freet, Brianna Evans, Timothy R Brick, et al.
Pageof 19